Biblio
The challenge to predict mobilized peripheral blood stem cells on the fourth day of G-CSF treatment in healthy donors: the predictive value of basal CD34+ cell and platelet counts. Biol Blood Marrow Transplant. 2019.
Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated Review. J Immunol Res. 2015;2015:968212.
. Haploidentical transplant with post-transplant cyclophosphamide for T-cell acute lymphoblastic leukemia: a report from the EBMT acute leukemia working party. Biol Blood Marrow Transplant. 2020.
High-dose chemotherapy and autologous hematopoietic stem cell transplantation as adjuvant treatment in high-risk breast cancer: data from the EBMT registry. Biol Blood Marrow Transplant. 2015.
High-dose chemotherapy for germ cell tumors: do we have a model?. Expert Opin Biol Ther. 2014:1-12.
. Impact of donor age and kinship on clinical outcomes after T-cell-replete haploidentical transplantation with PT-Cy. Blood Adv. 2020;4(16):3900-3912.
The impact of graft CD3/Tregs ratio on aGvHD and post-transplant outcome: a prospective multicenter study on patients with acute leukemia undergoing allogeneic peripheral blood stem cell transplantation. Transplant Cell Ther. 2021.
Impact of second-degree related donor on the outcomes of T cell-replete haploidentical transplantation with post-transplant cyclophosphamide. Bone Marrow Transplant. 2022.
An in-depth evaluation of acalabrutinib for the treatment of mantle-cell lymphoma. Expert Opin Pharmacother. 2019:1-10.
Individualized prediction of leukemia-free survival after autologous stem cell transplantation in acute myeloid leukemia. Cancer. 2019.
Integrating CAR-T cell therapy into the management of DLBCL: what we are learning. Expert Opin Biol Ther. 2023:1-9.
The power of telemedicine to improve CAR-T cell therapy programs: lessons learned from COVID-19 pandemic. Support Care Cancer. 2023;31(6):350.